Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer


Tonyali O., Coskun U., SENER N., İNANÇ M., Akman T., OKSUZOGLU B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.138, ss.2145-2151, 2012

  • Cilt numarası: 138 Konu: 12
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00432-012-1296-x
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayısı: ss.2145-2151

Özet

Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.